Samenvatting

Samenvatting Management Life Sciences Innovations

Samenvatting van de volgende artikelen: Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery, 8(12), 959-968. Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature reviews Drug discovery, 11(3), 191-200. Lo, A., & Pisano, G. (2016). Lessons from Hollywood: A new approach to funding R&D. MIT Sloan Management Review, 57(2), 47. Edmondson, A. C., Bohmer, R. M., & Pisano, G. P. (2001). Disrupted routines: Team learning and new technology implementation in hospitals. Administrative Science Quarterly, 46(4), 685-716. Metcalfe, J. S., James, A., & Mina, A. (2005). Emergent innovation systems and the delivery of clinical services: The case of intra-ocular lenses. Research Policy, 34(9), 1283-1304. Pisano, G.P. (2006) Chapter 5: The autonomy of a science-based business. In: Science business – the promise, the reality, and the future of biotech. Harvard Business School Press, Boston. Lehoux, P., Daudelin, G., Williams-Jones, B., Denis, J. L., & Longo, C. (2014). How do business model and health technology design influence each other? Insights from a longitudinal case study of three academic spin-offs. Research Policy, 43(6), 1025-1038. Willemstein, L., van der Valk, T., & Meeus, M. T. (2007). Dynamics in business models: An empirical analysis of medical biotechnology firms in the Netherlands. Technovation, 27(4), 221-232. Steinberg, D., Horwitz, G., & Zohar, D. (2015). Building a business model in digital medicine. Nature biotechnology, 33(9), 910-920. Sim, I. (2019). Mobile Devices and Health. New England Journal of Medicine, 381(10), 956-968. Boon, W.P.C. Universitair medisch centra als innovatiehubs. In: Boon, W.P.C. & Horlings, E. (2013) Kenniscoproductie voor de grote maatschappelijke vraagstukken. Rathenau Instituut, Den Haag. Christensen, C.M. (2009) Disrupting the hospital business model. In: The innovator’s prescription. McGraw-Hill, New York. Stolk, P. (2013). Background Paper 8.1: Public Private Partnerships. Retrieved from: Aerts, C., Sunyoto, T., Tediosi, F., & Sicuri, E. (2017). Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy. Arora, A., Fosfuri, A., & Gambardella, A. (2001) Markets for technology and their implications for corporate strategy. Industrial and corporate change, 10(2), 419- 451. Hopkins, M.M., P.A. Crane, P. Nightingale, C. Baden-Fuller (2013) Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009. Industrial and Corporate Change. Stuart, T.E., S.Z. Ozdemir, W.W. Ding (2007) Vertical alliance networks: the case of university-biotechnology-pharmaceutical alliance chains. Research Policy 36, 477-498. Powell, W. W., Koput, K. W., & Smith-Doerr, L. (1996). Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology. Administrative science quarterly, 116-145. Smits, R. E., & Boon, W. P. (2008). The role of users in innovation in the pharmaceutical industry. Drug Discovery Today, 13(7), 353-359. Gittelman, M. (2016). The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery. Research Policy, 45(8), 1570-1585. Blind, K. (2004) Chapter 2: A Conceptual Framework to Analyse the Relationship Between Innovation and Regulation. Pp. 3-16. In: New Products and Services: Analysis of Regulations Shaping New Markets. Fraunhofer Institute, Karlsruhe. Hansen, A. (2001). Biotechnology regulation: Limiting or contributing to biotech development?. New Genetics and Society, 20(3), 255-271. Carroll, A. B., & Shabana, K. M. (2010). The business case for corporate social responsibility: a review of concepts, research and practice. International Journal of Management Reviews, 12(1), 85-105. Schurman, R. (2004). Fighting “Frankenfoods”: Industry opportunity structures and the efficacy of the anti-biotech movement in Western Europe. Social Problems, 51(2), 243-268.